—

Caris Life Sciences, Inc. Common Stock (CAI) — the peer cohort

As of 2026-10-07 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Caris Life Sciences, Inc. Common Stock ranks 5 of 7 in its cohort on the Closelooknet composite (59/100) — the cohort is led by BB Biotech AG at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
CAI Caris Life Sciences, Inc. Common Stock 59 79 62 26 ok 19.5%
BION.SW BB Biotech AG 74 63 96 81 info 12.3%
ONC BeiGene, Ltd. 64 81 65 32 ok 5.5%
PTGX Protagonist Therapeutics Inc 60 77 62 12 info 12.4%
REGN Regeneron Pharmaceuticals Inc 60 60 72 52 watch 14%
CORT Corcept Therapeutics Incorporated 57 96 50 24 ok 5.4%
TGTX TG Therapeutics Inc 54 70 68 29 info 10.7%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-07

Quick answers

Who are Caris Life Sciences, Inc. Common Stock's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: BB Biotech AG (BION.SW), BeiGene, Ltd. (ONC), Protagonist Therapeutics Inc (PTGX), Regeneron Pharmaceuticals Inc (REGN), Corcept Therapeutics Incorporated (CORT), TG Therapeutics Inc (TGTX).

How does CAI score against its peers?

Caris Life Sciences, Inc. Common Stock's composite reads 59/100, ranking 5 of 7 in its cohort as of 2026-10-07; the cohort's highest composite is BB Biotech AG at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.